Recent clinical advances in CD73 blocking antibodies or antagonists and inhibitors of A2AR and A2BR have demonstrated the therapeutic potentials of modulating the adenosine pathway in cancer [8, 20, 23–25]. Here, ADORA2A is linked to cancer.